{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"The MTD was defined as the highest dose level at which less than 33% of participants experienced a DLT.","groups":[{"description":"* Cohort A1: 70 mg/m² abemaciclib administered orally BID in combination with 50 mg/m²/day irinotecan administered IV on Days 1-5 of each 21-day cycle and 100 mg/m²/day temozolomide administered orally on Days 1-5 of each 21-day cycle.\n* Cohort A-1: 55 mg/m² abemaciclib administered orally BID in combination with 50 mg/m²/day irinotecan administered IV on Days 1-5 of each 21-day cycle and 100 mg/m²/day temozolomide administered orally on Days 1-5 of each 21-day cycle.","id":"OG000","title":"Part A - Abemaciclib"}],"paramType":"NUMBER","populationDescription":"All part A participants who received at least one dose of abemaciclib and had evaluable data for this outcome.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (21 Days)","title":"Maximum Tolerated Dose (MTD) of Abemaciclib in Part A","type":"PRIMARY","unitOfMeasure":"mg/m² BID"}